

DAFTAR PUSTAKA

1. Loria P, Lonardo A, Carulli N. Should Nonalcoholic Fatty Liver Disease Be Renamed? *Digestive Diseases*. 2005;23(1):72–82.
2. Angulo P. Nonalcoholic Fatty Liver Disease. *New England Journal of Medicine*. 2002 Apr 18;346(16):1221–31.
3. Eslam M, Sarin SK, Wong VWS, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. *Hepatology*. 2020 Dec 1;71(6):889–919.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016 Jul 22;64(1):73–84.
5. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021 Nov;6(11):903–13.
6. Gast KB, Tjeerdema N, Stijnen T, Smit JWA, Dekkers OM. Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis. *PLoS One*. 2012 Dec 28;7(12):e52036.
7. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. *Nat Rev Endocrinol*. 2014 May 25;10(5):293–302.
8. Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. *Cells*. 2020 Mar 2;9(3):590.
9. Lee WH, Najjar SM, Kahn CR, Hinds TD. Hepatic insulin receptor: new views on the mechanisms of liver disease. *Metabolism*. 2023 Aug;145:155607.
10. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. *Metabolism*. 2016 Aug;65(8):1109–23.
11. Diehl KL, Vorac J, Hofmann K, Meiser P, Unterweger I, Kuerschner L, et al. Kupffer Cells Sense Free Fatty Acids and Regulate Hepatic Lipid Metabolism in High-Fat Diet and Inflammation. *Cells*. 2020 Oct 8;9(10):2258.
12. Miyake T, Furukawa S, Matsuura B, Yoshida O, Kanamoto A, Miyazaki M, et al. 1419-P: The Effect of Remnant Cholesterol on Pathophysiology of Metabolic Dysfunction–Associated Steatotic Liver. *Diabetes*. 2024 Jun 14;73(Supplement_1).
13. Kessoku T. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. *World J Gastroenterol*. 2014;20(29):10108.
14. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *J Gastroenterol Hepatol*. 2016 May 28;31(5):936–44.
15. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, et al. Gender-Specific Differences in Adipose Distribution and Adipocytokines Influence Adolescent Nonalcoholic Fatty Liver Disease. *Hepatology*. 2011 Mar;53(3):800–9.

16. Wu W, Chen G, Wu K, Zheng H, Chen Y, Wang X, et al. Cumulative exposure to high remnant-cholesterol concentrations increases the risk of cardiovascular disease in patients with hypertension: a prospective cohort study. *Cardiovasc Diabetol*. 2023 Sep 21;22(1):258.
17. Jung U, Choi MS. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. *Int J Mol Sci*. 2014 Apr 11;15(4):6184–223.
18. Ohnishi H, Saitoh S, Takagi S, Ohata J ichi, Isobe T, Kikuchi Y, et al. Relationship between insulin-resistance and remnant-like particle cholesterol. *Atherosclerosis*. 2002 Sep;164(1):167–70.
19. Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, et al. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. *Int J Environ Res Public Health*. 2022 Feb 13;19(4):2096.
20. Rachmatullah TF, Permatadewi CO, Hutami HT, Limantoro C, Purnomo MPHD. Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) with Left Ventricular Mass Index (LVMI) in patients with NAFLD. *Journal of Biomedicine and Translational Research*. 2021 Aug 31;7(2):79–85.
21. Mathews SE, Kumar RB, Shukla AP. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. *Curr Opin Endocrinol Diabetes Obes*. 2018 Oct;25(5):315–20.
22. Day CP, James OFW. Steatohepatitis: A tale of two “hits”? *Gastroenterology*. 1998 Apr;114(4):842–5.
23. Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. *Atherosclerosis*. 2019 Mar;282:110–20.
24. Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, et al. Human-based systems: Mechanistic NASH modelling just around the corner? *Pharmacol Res*. 2018 Aug;134:257–67.
25. Nuraini IS, Sulchan M, Dieny FF. Resistensi insulin pada remaja stunted obesity usia 15-18 tahun di Kota Semarang. *Journal of Nutrition College*. 2017 Jul 20;6(2):164.
26. Han AL. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. *Diabetol Metab Syndr*. 2022 Dec 22;14(1):44.
27. Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Insulin resistance: An adaptive mechanism becomes maladaptive in the current environment — An evolutionary perspective. *Metabolism*. 2013 May;62(5):622–33.
28. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AI. Iron and insulin resistance. *Aliment Pharmacol Ther*. 2005 Nov 14;22(s2):61–3.
29. Bermudez V, Salazar J, Martínez MS, Chávez-Castillo M, Olivar LC, Calvo MJ, et al. Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela. *Adv Prev Med*. 2016;2016:1–13.
30. Singh B. Surrogate markers of insulin resistance: A review. *World J Diabetes*. 2010;1(2):36.

31. Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. *Drug Discov Ther.* 2015;9(6):380–5.
32. Wang Z, Li M, Xie J, Gong J, Liu N. Association between remnant cholesterol and arterial stiffness: A secondary analysis based on a cross-sectional study. *The Journal of Clinical Hypertension.* 2022 Jan 9;24(1):26–37.
33. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. *Eur Heart J.* 2013 Jun 21;34(24):1826–33.
34. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. *Endocr Rev.* 2019 Apr 1;40(2):537–57.
35. Heo JH, Jo SH. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease. *J Korean Med Sci.* 2023;38(38).
36. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. *Eur Heart J.* 2020 Jan 1;41(1):99–109c.
37. Stürzebecher PE, Katzmann JL, Laufs U. What is ‘remnant cholesterol’? *Eur Heart J.* 2023 Apr 21;44(16):1446–8.
38. Hoogeveen RC, Ballantyne CM. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. *Clin Chem.* 2021 Jan 8;67(1):143–53.
39. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *The Lancet.* 2014 Aug;384(9943):626–35.
40. Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. *JHEP Reports.* 2020 Dec;2(6):100150.
41. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. *Diab Vasc Dis Res.* 2019 Mar 15;16(2):118–27.
42. Khan RS, Bril F, Cusi K, Newsome PN. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. *Hepatology.* 2019 Aug 19;70(2):711–24.
43. Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, et al. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. *SAGE Open Med.* 2020;8:2050312120933804.
44. Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. *Int J Mol Sci.* 2021 Apr 16;22(8):4156.
45. Huang H, Xie J, Zeng Y, Liu Z, Miao M, Xu L, et al. Remnant Cholesterol Independently Predicts the Development of Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab.* 2023 Oct 18;108(11):2907–15.
46. Joshi PH, Khokhar AA, Massaro JM, Littere ST, Griswold ME, Martin SS, et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. *J Am Heart Assoc.* 2016 May 6;5(5).
47. Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. *Wellcome Open Res.* 2019 Sep 19;3:166.

48. Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. *JHEP Reports*. 2020 Dec;2(6):100150.
49. Campanella A, Iacovazzi PA, Misciagna G, Bonfiglio C, Mirizzi A, Franco I, et al. The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis. *Nutrients*. 2020 Jun 4;12(6):1674.
50. Miao Y, Tao H. Association between remnant lipoprotein cholesterol levels and risk of non-alcoholic fatty liver disease in non-obese populations: a Chinese longitudinal prospective cohort study. *BMJ Open*. 2023 May 5;13(5):e069440.
51. Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. *Eur J Gastroenterol Hepatol*. 2010 Jan;22(1):24–32.
52. Guo Z, Wu D, Mao R, Yao Z, Wu Q, Lv W. Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. *Sci Rep*. 2025 Feb 27;15(1):7083.
53. Estes C, Chan HLY, Chien RN, Chuang W, Fung J, Goh GBB, et al. Modelling NAFLD disease burden in four Asian regions—2019-2030. *Aliment Pharmacol Ther*. 2020 Apr 4;51(8):801–11.
54. Wang S, Zhang Q, Qin B. Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease. *Sci Rep*. 2024 Feb 26;14(1):4596.
55. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013 Jun 19;10(6):330–44.
56. Birkenfeld AL, Shulman GI. Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes. *Hepatology*. 2014 Feb;59(2):713–23.
57. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. *Am J Med*. 2011 Jan;124(1):69–76.
58. Guven Cetin E. The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. *Sisli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital*. 2020;411–5.
59. Pastori D, Baratta F, Novo M, Cocomello N, Violi F, Angelico F, et al. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. *J Clin Med*. 2018 Oct 23;7(11):378.
60. Tang J, Tang T, Yu Q, Tong X, Liu C, Chen C, et al. Association Between Remnant Cholesterol and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis. *Metab Syndr Relat Disord*. 2024 Nov 1;22(9):637–45.
61. Hao X, Li D, Huang X, Wang T, Wu P, Shen L, et al. Remnant cholesterol, a potential risk factor of metabolic dysfunction-associated fatty liver disease. *Nutr Metab (Lond)*. 2025 Feb 18;22(1):13.
62. Ai M, Tanaka A, Ogita K, Sekine M, Numano F, Numano F, et al. Relationship between Hyperinsulinemia and Remnant Lipoprotein Concentrations in Patients with Impaired Glucose Tolerance. *J Clin Endocrinol Metab*. 2000 Oct;85(10):3557–60.

63. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. *Diabetes Care*. 2000 Dec 1;23(12):1766–9.
64. Lee, M. H., & Park, S. K. Association of remnant cholesterol with non-alcoholic fatty liver disease and related metabolic disorders. *Journal of Hepatology*, 2018 68(5), 941-948.
65. Saito, Y., Nakamura, S., & Ohira, T. Remnant cholesterol and the risk of non-alcoholic fatty liver disease. *Diabetes, Obesity and Metabolism*, 2019.21(8), 1923-1930.